Actively Recruiting
Evaluating AK104 Combined With Chemotherapy as Neoadjuvant Treatment in Advanced Ovarian Cancer A Randomized Controlled Study
Led by Anhui Provincial Hospital · Updated on 2026-10-28
100
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of AK104, a PD-1CTLA-4 bispecific antibody, combined with chemotherapy as a neoadjuvant treatment for women with advanced ovarian cancer at high perioperative risk or who are unlikely to achieve complete tumor removal R0 resection before initial surgery. This Phase 3 randomized controlled trial compares this combination therapy to chemotherapy alone in patients with FIGO 2018 stage III-IV ovarian cancer. The goal is to assess whether adding AK104 improves treatment outcomes while monitoring safety. Participants in the experimental group receive AK104 at 10 mgkg by intravenous infusion every three weeks for 3 to 4 cycles, determined by the investigator, alongside a chemotherapy regimen selected from paclitaxel plus carboplatin or paclitaxel albumin-bound plus carboplatin or cisplatin. The chemotherapy-only group receives the same chemotherapy regimens without AK104 for 3 to 4 cycles. Each dosing cycle lasts 3 weeks, with treatments continuing unless intolerable side effects occur, consent is withdrawn, or other discontinuation criteria are met. Infusions last about 60 minutes but can be extended up to 120 minutes if needed. Before each treatment cycle, participants undergo evaluations including vital signs, physical exams, laboratory tests, and physical status scoring to assess safety and tolerability. Researchers measure the rate of complete tumor removal R0 rate up to 6 months after treatment, as well as overall response rate, disease control rate, pathological complete response, progression-free survival, and adverse events up to one year. The study includes follow-up assessments to monitor these outcomes, with total participation lasting several months.
CONDITIONS
Brief Title
Efficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer
Research Team
Y
Ying Zhou
H
Hanjie Xu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here